Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + SBRT in locally advanced pancreatic cancer
NCT06009029Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of zimberelimab in pancreatic cancer (PC), sponsored by Peking University Third Hospital. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06009029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009029.